LLY Jan 2025 420.000 put
| Previous close | 2.1800 |
| Open | 2.1800 |
| Bid | 1.0000 |
| Ask | 2.5000 |
| Strike | 420.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.1800 - 2.1800 |
| Contract range | N/A |
| Volume | |
| Open interest | 377 |
BloombergInvestors Pile Into Amgen in Search of Next Obesity Drug Payout
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackBuffett Praises Apple After Trimming It, Drops Paramount StakeTreasury Rally Risks Running Into a $125 Billion Brick WallFrance’s Macron Calls for Reset of Economic Ties With ChinaLamborghini Bros No More: Crypto Is Creating a New Wealth EffectThe shares
Barrons.comAmazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
Amazon reported strong first-quarter results, with revenue and operating income ahead of expectations. The company delivered operating income of $15.3 billion, above consensus of $11.3 billion, while reporting better-than-expected growth in both Amazon Web Services (+17.2% year over year versus Street +15%) and advertising (+24.3% Y/Y versus Street +23.5%). Amazon has now reported operating income above the high end of its guidance range for five consecutive quarters, and the company has a number of drivers for further margin expansion in place, including continued cost efficiencies within its fulfillment network as well as the ongoing mix shift toward higher-margin AWS and advertising revenue.
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
